Abstract
From the laboratory and clinical studies on lividomycin, a new antibiotic of the aminoglycoside group produced by Streptomyces lividus, the following results were obtained.
1.The MIC values of lividomycin against newly isolated Staphylococcus aureus (20 strains) were lower than those of kanamycin.
2. The bacteriolytic activity of lividomycin on the growth curve of S.aureus FDA 209 P strain was observed using Biophotometer Jouan.The same activity against FDA 209 P strain was observed in the sera of the patients injected intramuscularly with 500-5,000mg lividomycin.The sera taken 30minutes, 1 hour and 3 hours after the injection of 1,000mg were active, but that taken after 6 hours was inactive.
3. Thirty cases of otorhinolaryngeal patients were treated with lividomycin.There were 16 remarkably effective cases (53.3 %), 7 improved cases (23.4%), and 7 ineffective cases (23.4%).Lividomycin was effective in 76.7 % of the patients treated.
4. As for the side effects of lividomycin, eruption or ototoxicity was not encountered.
